harrowinc.com (HROW): Dhuwit awis perusahaan

Tandha merek Harrow (HROW)

Harrow, Inc. (HROW) free cash flow demonstrates a steady growth trajectory amid rising demand for cataract surgery. Harrow, Inc. (HROW) revenues are based on the sales of branded drugs VEVYE and IHEEZO, although generic expansion and corporate pressure create risks for profits. The value of 0.08 determines the latest liquidity valuation metric, confirming the business's current financial strength reserve.

HROW - Aset likuid perusahaan Harrow Health ing rentang 04.07.2022 - 21.11.2026

Rincian metrik lan analitis perusahaan Harrow Health (HROW)

- rega saiki lan proyeksi nilai saham:
Analisis dhasar perusahaan:Harrow, Inc.
Produk merek Harrow Inc

Investors are verifying the issuer's solvency by comparing current liquid reserves against the debt load using a system of financial multiples. An analysis of the cash position allows for an assessment of funds available at the close of the session, which for ophthalmology market leader Harrow, Inc. (HROW) confirms the ability to maintain diversified supply chains in the US without relying on expensive external financing.